Skip to main content
SpringerLink
Log in

Non-atherosclerotic Vascular Disease: Vasculitis, Popliteal Entrapment, Hypercoagulable

  • Chapter
  • First Online:
Essentials of Vascular Surgery for the General Surgeon

  • 2212 Accesses

Abstract

Vascular disease usually involves arterial stenosis, aneurysms, and dissections caused by atherosclerosis. The high prevalence of atherosclerosis ensures that most general surgeons have experience managing patients with traditional vascular disease. In contrast, non-atheroslcerotic disorders affecting the arteries and veins occur less frequently and may not be familiar to most clinicians. Left untreated, non-atherosclerotic vascular conditions can have serious and potentially fatal consequences. This chapter reviews clinically relevant non-atherosclerotic vascular diseases including hypercoagulable states, popliteal entrapment syndrome, Buerger’s disease, vasculitis, and fibromuscular dysplasia. Patients with these disorders differ from traditional vascular patients by age, comorbidities, presentation, and treatment. A basic understanding of non-atherosclerotic vascular disease can help general surgeons recognize and appropriately manage patients with these rare conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med. 2000; 51:169–85.

    PubMed  CAS  Google Scholar 

  2. Rao AK, Sheth S, Kaplan R. Inherited hypercoagulable states. Vasc Med. 1997;2:313–20.

    PubMed  CAS  Google Scholar 

  3. Ray SA, Rowley MR, Loh A, et al. Hypercoagulable states in patients with leg ischemia. Br J Surg. 1994;81:811–4.

    PubMed  CAS  Google Scholar 

  4. Eldrup-Jorgensen J, Flanigan DP, Brace L, et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg. 1989;9:334–41.

    PubMed  CAS  Google Scholar 

  5. Donaldson MC, Weinberg DS, Belkin M, et al. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. J Vasc Surg. 1990;11:825–31.

    PubMed  CAS  Google Scholar 

  6. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med. 2003;138(2):128–34.

    PubMed  Google Scholar 

  7. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516–30.

    PubMed  CAS  Google Scholar 

  8. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism. Results of the Spanish Multicentric Study on Thrombophilia (EMET-study). Thromb Haemost. 1997;77:444.

    PubMed  CAS  Google Scholar 

  9. Van Den Belt AGM, Huisman MV, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost. 1996; 2(4):227–36.

    Google Scholar 

  10. Weiss P, Soff GA, Halkin H, et al. Decline of protein C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res. 1987;45(6):783–90.

    PubMed  CAS  Google Scholar 

  11. Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost. 1997;78:351.

    PubMed  CAS  Google Scholar 

  12. Clark DA, Williams WL, Marlar RA. Mesenteric vein thrombosis associated with familial deficiency of free protein S. Arch Pathol Lab Med. 1991;115:617.

    PubMed  CAS  Google Scholar 

  13. Baglin T, Gray E, Greaves M, et al. British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149:209–20.

    Google Scholar 

  14. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643–50.

    PubMed  CAS  Google Scholar 

  15. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133–4.

    PubMed  CAS  Google Scholar 

  16. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503–6.

    PubMed  CAS  Google Scholar 

  17. Leroyer C, Mercier B, Escoffe M, et al. Factor V Leiden prevalence in venous thromboembolism patients. Chest. 1997;111:1603–6.

    PubMed  CAS  Google Scholar 

  18. Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr Opin Rheumatol. 2012;24:1–7.

    Google Scholar 

  19. Hellgren M, Svensson PI, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210.

    PubMed  CAS  Google Scholar 

  20. Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 1995;91:465–70.

    PubMed  CAS  Google Scholar 

  21. Henkens CMA, van der Bom JG, van der Meer FJ. Lowered activated protein C-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost. 1995;74:1198–9.

    PubMed  CAS  Google Scholar 

  22. Cumming AM, Tait RC, Fildes S, Young A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90:725–7.

    PubMed  CAS  Google Scholar 

  23. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–7.

    PubMed  CAS  Google Scholar 

  24. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183–8.

    PubMed  CAS  Google Scholar 

  25. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777–82.

    PubMed  CAS  Google Scholar 

  26. Gandrille S, Greengard JS, Alhenc-Gelas M, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood. 1995;86:219–24.

    PubMed  CAS  Google Scholar 

  27. Zoller B, Holm J, Svensson P, Dahlback B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC resistance) and/or inherited protein S deficiency. Thromb Haemost. 1996;75:270–4.

    PubMed  CAS  Google Scholar 

  28. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost. 1996;76(6):824–34.

    PubMed  CAS  Google Scholar 

  29. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation. 1999; 99:999–1004.

    PubMed  CAS  Google Scholar 

  30. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800–2.

    PubMed  CAS  Google Scholar 

  31. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997; 336:399–403.

    PubMed  CAS  Google Scholar 

  32. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 340:901–7.

    PubMed  CAS  Google Scholar 

  33. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77(4):624–8.

    PubMed  CAS  Google Scholar 

  34. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998;97(11):1037–41.

    PubMed  CAS  Google Scholar 

  35. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographic distribution of the 20210 G to a prothrombin variant. Thromb Haemost. 1998;79:706–8.

    PubMed  CAS  Google Scholar 

  36. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152.

    PubMed  CAS  Google Scholar 

  37. O’Donnell JO, Tuddenham EGD, Manning R, et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to acute phase reaction. Thromb Haemost. 1997;77:825.

    PubMed  Google Scholar 

  38. Kamphusien PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001;21:731.

    Google Scholar 

  39. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–81.

    PubMed  CAS  Google Scholar 

  40. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149–55.

    PubMed  CAS  Google Scholar 

  41. den Heijer M, Koster T, Bloom HJ, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med. 1996;334:759–62.

    Google Scholar 

  42. Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep-vein thrombosis: a case controlled study. Thromb Haemost. 1996;76:883.

    PubMed  CAS  Google Scholar 

  43. Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–9.

    PubMed  CAS  Google Scholar 

  44. Nygard O, Nordrehaug JE, Refusum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230.

    PubMed  CAS  Google Scholar 

  45. Lim W, Crowther MA. Antiphospholipid antibodies: a critical review of the literature. Curr Opin Hematol. 2007;14:494.

    PubMed  CAS  Google Scholar 

  46. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295.

    PubMed  CAS  Google Scholar 

  47. Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome. A 5 year prospective study. Stroke. 2005;36:1490.

    PubMed  Google Scholar 

  48. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303.

    PubMed  CAS  Google Scholar 

  49. Khamashta MA, Cuadrado MD, Mukic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med. 1995;332:993.

    PubMed  CAS  Google Scholar 

  50. de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993.

    PubMed  Google Scholar 

  51. Trousseau A. Phlegmasia Alba Dolen. In: Clinique Medicale De L’Hotel-Dieu de Paris. Paris: JB Balliere; 1865. p. 654.

    Google Scholar 

  52. Blom JW, Doggen CJ, Osanto S, Roendaal FR. Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA. 2005;293:715–22.

    PubMed  CAS  Google Scholar 

  53. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146–53.

    PubMed  CAS  Google Scholar 

  54. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119:1062.

    Google Scholar 

  55. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484.

    PubMed  CAS  Google Scholar 

  56. Heit JA, Kobervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30 year population-based study. Ann Intern Med. 2005;143:697.

    PubMed  Google Scholar 

  57. Andres RL, Miles A. Venous thromboembolism and pregnancy. Obstet Gynecol Clin North Am. 2001;28:613.

    PubMed  CAS  Google Scholar 

  58. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol. 2005; 193:216.

    PubMed  Google Scholar 

  59. Faught W, Garner P, Jones G, et al. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol. 1995;172:147.

    PubMed  CAS  Google Scholar 

  60. Comp PC, Thurnau GR, Welsh J, et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 1986;68:881.

    PubMed  CAS  Google Scholar 

  61. Johnson CM, Mureebe L, Silver D. Hypercoagulable states: a review. Vasc Endovascular Surg. 2005;39(2):123–33.

    PubMed  Google Scholar 

  62. Ginsberg J, Brill-Edwards P, Burrows RF, et al. DVT during pregnancy: leg and trimester presentation. Thromb Haemost. 1992; 67:519.

    PubMed  CAS  Google Scholar 

  63. Martinelli I, DeStafano V, Taioli E, et al. Inherited thrombophilias and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002;87:791–5.

    PubMed  CAS  Google Scholar 

  64. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(4 Suppl 5):9.

    PubMed  CAS  Google Scholar 

  65. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804.

    PubMed  CAS  Google Scholar 

  66. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198–202.

    PubMed  CAS  Google Scholar 

  67. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):7S–47S.

    Google Scholar 

  68. Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 1991; 1S:S3–10.

    Google Scholar 

  69. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S–453.

    PubMed  CAS  Google Scholar 

  70. Anderson JA, Weitz J. Hypercoagulable states. Crit Care Clin. 2011;27:933–52.

    PubMed  Google Scholar 

  71. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95: 315–28.

    PubMed  CAS  Google Scholar 

  72. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423–8.

    PubMed  CAS  Google Scholar 

  73. Schafer AI, Levine MN, Konkle BA, et al. Thrombotic disorders: diagnosis and treatment. Hematology. 2003;520–39.

    Google Scholar 

  74. Stuart TP. Note on a variation in the course of the popliteal artery. J Anat Physiol. 1879;13:162.

    PubMed  CAS  PubMed Central  Google Scholar 

  75. Hamming JJ. Intermittent claudication at an early age, due to an anomalous course of the popliteal artery. Angiology. 1959;10: 369–70.

    PubMed  CAS  Google Scholar 

  76. Bouhoutsos J, Daskalakis E. Muscular abnormalities affecting the popliteal vessels. Br J Surg. 1981;68:501–6.

    PubMed  CAS  Google Scholar 

  77. Gibson MHL, Mills JG, Johnson GE, et al. Popliteal entrapment syndrome. Ann Surg. 1977;185:341–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  78. Turnipseed WD. Popliteal entrapment syndrome. J Vasc Surg. 2002;35:910–5.

    PubMed  Google Scholar 

  79. Turnipseed WD. Clinical review of patients treated for atypical claudication: a 28-year experience. J Vasc Surg. 2004;40:79–85.

    PubMed  Google Scholar 

  80. Rignault DP, Pailler JL, Lunel F. The “functional” popliteal entrapment syndrome. Int Angiol. 1985;4:341–3.

    PubMed  CAS  Google Scholar 

  81. Pillai J. A current interpretation of popliteal vascular entrapment. J Vasc Surg. 2008;48:61S–5.

    PubMed  Google Scholar 

  82. Chernoff DM, Walker AT, Khorasani R, et al. Asymptomatic functional popliteal artery entrapment: demonstration at MR imaging. Radiology. 1995;195:176–80.

    PubMed  CAS  Google Scholar 

  83. Turnipseed WD, Pozniak M. Popliteal entrapment as a result of neurovascular compression by the soleus and plantaris muscles. J Vasc Surg. 1992;15:285–94.

    PubMed  CAS  Google Scholar 

  84. Sinha S, Houghton J, Holt P, et al. Popliteal entrapment syndrome. J Vasc Surg. 2012;55(1):252–62.

    PubMed  Google Scholar 

  85. Roche-Nagle G, Wong KT, Oreopolulos G. Vascular claudication in a young patient: popliteal entrapment syndrome. Hong Kong Med J. 2009;15(5):388–90.

    PubMed  Google Scholar 

  86. Ehsan O, Darwish A, Edmundson C, et al. Non-traumatic lower limb vascular complications in endurance athletes. Review of literature. Eur J Vasc Endovasc Surg. 2004;28:1–8.

    PubMed  CAS  Google Scholar 

  87. Levien L. Popliteal artery thrombosis caused by popliteal entrapment syndrome. In: Greenhalgh RM, Powell JT, editors. Inflammatory and thrombotic problems in vascular surgery. London: WB Saunders Co Ltd; 1997. p. 159–68.

    Google Scholar 

  88. Gibson MHL, Mills JG, Johnson GE, et al. Popliteal entrapment syndrome. Ann Surg. 1997;185:341–8.

    Google Scholar 

  89. Murray A, Halliday M, Croft RJ. Popliteal artery entrapment syndrome. Br J Surg. 1991;78:1414–9.

    PubMed  CAS  Google Scholar 

  90. Di Cesare J, Marsili L, Marino G, Masciocchi C, et al. Stress MR imaging for evaluation of popliteal artery entrapment. J Magn Reson Imaging. 1994;4:617–22.

    PubMed  Google Scholar 

  91. Collins PS, McDonald PT, Lim RC. Popliteal artery entrapment: an evolving syndrome. J Vasc Surg. 1989;10:484–90.

    PubMed  CAS  Google Scholar 

  92. Zund G, Brunner U. Surgical aspects of popliteal artery entrapment syndrome: 26 years of experience with 26 legs. Vasa. 1995; 24:29–33.

    PubMed  CAS  Google Scholar 

  93. DiMarzo L, Cavallaro A, Mingoli A, et al. Popliteal artery entrapment syndrome: the role of early diagnosis and treatment. Surg. 1997;122:26–31.

    Google Scholar 

  94. DiMarzo L, Cavallaro A, Sciacca V, et al. Natural history of entrapment of the popliteal artery. J Am Coll Surg. 1994;178: 553–6.

    CAS  Google Scholar 

  95. Akkersdijk WL, de Ruyter JW, Lapham R, et al. Colour duplex ultrasonographic imaging and provocation of popliteal artery compression. Eur J Vasc Endovasc Surg. 1995;10:342–5.

    PubMed  CAS  Google Scholar 

  96. Deshpande A, Denton M. Functional popliteal entrapment syndrome. Aust N Z J Surg. 1998;68:660–3.

    PubMed  CAS  Google Scholar 

  97. Kim SY, Min SK, Ahn S, et al. Long-term outcomes after revascularization for advanced popliteal artery entrapment syndrome with segmental arterial occlusion. J Vasc Surg. 2012;55(1): 90–7.

    PubMed  Google Scholar 

  98. Papaioannou S, Tsitouridis K, Giataganas G, et al. Evaluation of popliteal arteries with CT angiography in popliteal artery entrapment syndrome. Hippokratia. 2009;13:32–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  99. Rich NM, Collins Jr GJ, McDonald PT, et al. Popliteal vascular entrapment. Its increasing interest. Arch Surg. 1979;114: 1377–84.

    PubMed  CAS  Google Scholar 

  100. Espinoza LR. Buerger’s disease: thromboangitis obliterans 100 years after the initial description. Am J Med Sci. 2009;337(4): 285–6.

    PubMed  Google Scholar 

  101. Piazza G, Creager M. Thromboangitis obliterans. Circulation. 2010;121:1858–61.

    PubMed  PubMed Central  Google Scholar 

  102. Puechal X, Fiessinger JN, Kahan A, et al. Rheumatologic manifestations in patients with thromboangitis obliterans. J Rheumatol. 1999;26:1764–8.

    PubMed  CAS  Google Scholar 

  103. Olin JW. Thromboangitis obliterans. N Engl J Med. 2000;343: 864–9.

    PubMed  CAS  Google Scholar 

  104. Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2001;39:176–80.

    Google Scholar 

  105. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol. 2001;13:48–55.

    PubMed  CAS  Google Scholar 

  106. Luqmani R. Large vessel vasculitides. Update for the cardiologist. Curr Opin Cardiol. 2012;27(6):578–84.

    PubMed  Google Scholar 

  107. Devauchell-Pensec V, Jousee S, Destombe C, et al. Epidemiology, imaging and treatment of GCA. Joint Bone Spine. 2008;75(3): 267–72.

    Google Scholar 

  108. Weyand C, Liao JY, Goronzy JJ, et al. The immunopathology of GCA: diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32(3):259–65.

    PubMed  Google Scholar 

  109. Wlavick MD, Walvick MP. GCA: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118:1201–4.

    Google Scholar 

  110. Danesh-Meyer H. Temporal artery biopsy: skip it at your patient’s peril. Am J Ophthalmol. 2012;154(4):617–9.

    PubMed  Google Scholar 

  111. Quinn EM, Kearney DE, Keohane C. Temporal artery biopsy is not required in all cases of suspected GCA. Ann Vasc Surg. 2012;26(5):649–54.

    PubMed  Google Scholar 

  112. Cowey S, Reynolds C, Joglekar S, et al. Does temporal artery biopsy influence management of GCA? Int J Surg. 2010;8:501.

    Google Scholar 

  113. Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous glucocorticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994; 120:987–92.

    PubMed  CAS  Google Scholar 

  114. Dastgir G, Gutman J, Shinder R. Facial nerve injury: a complication of superficial temporal artery biopsy. Am J Ophthalmol. 2011;153(1):187.

    Google Scholar 

  115. Ypilantis E, Courtney ED, Chopra N, et al. Importance of specimen length during temporal artery biopsy. Br J Surgery. 2011; 98:1556–60.

    Google Scholar 

  116. Scafer V, Zwerina J. Biologic treatment of large vessel vasculitides. Curr Opin Rheumatol. 2012;24(1):31–7.

    Google Scholar 

  117. Talwar KD, Kumar K, Copra P, et al. Cardiac involvement in non-specific arteritis. Am Heart J. 1991;122:1666–70.

    PubMed  CAS  Google Scholar 

  118. Curry TK, Messina LM. Fibromuscular dysplasia: when is intervention warranted? Semin Vasc Surg. 2003;16(3):190–9.

    PubMed  Google Scholar 

  119. Bornak A, Milner R. Diagnosing and treating atypical arterial pathologies of aortic arch vessels: dissection and fibromuscular dysplasia. Semin Vasc Surg. 2011;24:36–43.

    PubMed  Google Scholar 

  120. Olin JW, Froehlich J, Xiaokui G, et al. The United States registry for fibromuscular dysplasia results in the first 447 patients. Circulation. 2012;125:3182–90.

    PubMed  Google Scholar 

  121. Weinberg I, Jaff MR. Nonatherosclerotic disorders of the lower extremities. Circulation. 2012;126:213–22.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Vascular Surgery, Department of Surgery, Kaleida Health Buffalo General Medical Center, 100 High Street B-7, Buffalo, NY, 14203, USA

    Linda M. Harris MD

  2. Department of Surgery, Erie County Medical Center, University of Buffalo, Buffalo, NY, USA

    James Lukan MD

Authors
  1. Linda M. Harris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Lukan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda M. Harris MD .

Editor information

Editors and Affiliations

  1. Chief, Division of Vascular Surgery and Endovascular Services, and Lead Physician, Vascular Surgery Department of Veterans Affairs Healthcare, SUNY Upstate Medical University, and Network Upstate New York at Syracuse, Syracuse, New York, USA

    Vivian Gahtan

  2. Director of Endovascular Services, Division of Vascular Surgery and Endovascular Services, and Vascular Surgeon, Department of Veterans Affairs Healthcare, SUNY Upstate Medical University, and Network Upstate New York at Syracuse, Syracuse, New York, USA

    Michael J. Costanza

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Harris, L.M., Lukan, J. (2015). Non-atherosclerotic Vascular Disease: Vasculitis, Popliteal Entrapment, Hypercoagulable. In: Gahtan, V., Costanza, M. (eds) Essentials of Vascular Surgery for the General Surgeon. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1326-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1326-8_22

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1325-1

  • Online ISBN: 978-1-4939-1326-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation